May 17th 2024
Dose reductions of ribociclib plus an NSAI did not decrease the regimen’s efficacy in patients with HR-positive, HER2-negative early breast cancer.
NVL-655 has received FDA breakthrough therapy designation for patients with pretreated ALK-positive non-small cell lung cancer.
May 16th 2024
Trastuzumab deruxtecan demonstrated superior long-term survival and response rates vs treatment of physician’s choice in HER2-positive breast cancer.
May 15th 2024
Olaparib, durvalumab, and fulvestrant produced a 66.7% 24-week PFS rate in patients with endocrine-resistant, ER-positive, HER2-negative breast cancer.
May 14th 2024
Petros Grivas, MD, PhD, discusses the significance of the phase 3 JAVELIN Bladder 100, EV-302, and CheckMate 901 trials in urothelial cancer.
May 13th 2024
The FDA has granted breakthrough therapy designation to petosemtamab in recurrent or metastatic head and neck squamous cell carcinoma.
May 10th 2024
Joaquim Bellmunt, MD, PhD, discusses the impact of enfortumab vedotin plus pembrolizumab on the treatment paradigm in first-line urothelial cancer.
SNB-101 has received FDA fast track designation for potential use in patients with small cell lung cancer.
May 9th 2024
Prolonged administration of imatinib maintenance therapy for 6 years improved disease-free survival in patients with gastrointestinal stromal tumors.
May 8th 2024
R. Wendel Naumann, MD, highlights endometrial cancer case studies and how they represent changes in this treatment paradigm.
Emil Lou, MD, PhD, FACP, discusses the predictive and prognostic use of tumor stroma proportion for outcomes and chemoresistance in ovarian cancer.
May 7th 2024
R. Wendel Naumann, MD, discusses 2 case studies in platinum-resistant ovarian cancer and the optimal treatment approaches for each patient.
Amandeep Salhotra, MD, discusses the feasibility and safety of Orca-T graft in patients undergoing allogeneic transplant for hematologic malignancies.
May 3rd 2024
The CAR T-cell therapy NXC-201 has received orphan drug designation from the European Commission for patients with multiple myeloma.
May 1st 2024
Karim Chamie, MD, discusses the significance of the FDA approval of N-803 plus BCG in BCG-unresponsive non–muscle invasive bladder cancer.
April 30th 2024
Chidamide plus R-CHOP has received approval from China’s NMPA for the management of diffuse large B-cell lymphoma.
April 29th 2024
Samer A. Srour, MB ChB, MS, explains the significance of early safety and efficacy data with CTX130 in CD70-expressing clear cell renal cell carcinoma.
April 26th 2024
Rohan Garje, MD, highlights advances made in precision medicine approaches for the management of metastatic prostate cancer.
Kara N. Maxwell, MD, PhD, discusses the prevalence of germline mutations in racially diverse cohorts of patients with metastatic prostate cancer.
April 25th 2024
Topline findings with the next-generation ColoAlert® test demonstrated 92% sensitivity and 90% specificity rates for colorectal cancer detection.